Drug Development

HIF-PH inhibitor increases hemoglobin levels in preclinical study of chronic anemia

Published in Blood Weekly, January 19th, 2006

FibroGen announced results from a preclinical study indicating that FG-2216, an investigational HIF-PH inhibitor for treating anemia, administered orally twice weekly for 6 months was safe and well tolerated in non-human primates and stimulated increases in hemoglobin levels, which were dose dependent and stable for the duration of therapy at each dose level.

In addition, FG-2216 prevented reduction in hemoglobin levels due to phlebotomy in this model of chronic anemia. There were no clinical adverse events or significant changes in serum chemistry or renal or hepatic parameters observed over the treatment period.

The study was conducted by the...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Blood Weekly

Source: Blood Weekly (2006-01-19)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry